Ethnic differences in pharmacogenomic variants: a south Asian perspective

References

• 1. Schwarz UI, Gulilat M, Kim RB. The role of next-generation sequencing in pharmacogenetics and pharmacogenomics. Cold Spring Harb. Perspect. Med. 9(2), doi: 10.1101/cshperspect.a033027 (2019).
  MedlineGoogle Scholar
• 2. Roden DM, George AL Jr. The genetic basis of variability in drug responses. Nat. Rev. Drug Discov. 1(1), 37–44 (2002).
  Medline CASGoogle Scholar
• 3. Caudle KE, Klein TE, Hoffman JM et al. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr. Drug Metab. 15(2), 209–17 (2014). https://cpicpgx.org/guidelines/
  Medline CASGoogle Scholar
• 4. CPIC. Guidelines. https://cpicpgx.org/guidelines/
  Google Scholar
• 5. US Food and Drug Administration Center for Drug Evaluation Research. Table of pharmacogenomic biomarkers in drug labeling (2023). www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling
  Google Scholar
• 6. Sharma S, Mariño-Ramírez L, Jordan IK. Race, ethnicity, and pharmacogenomic variation in the United States and the United Kingdom. Pharmaceutics 15(7), doi: 10.3390/pharmaceutics15071923 (2023).
  Google Scholar
• 7. Thiers FA, Sinskey AJ, Berndt ER. Trends in the globalization of clinical trials. Nat. Rev. Drug Discov. 7(1), 13–14.
  Google Scholar
• 8. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 356(9237), 1255–1259 (2000).
  Medline CASGoogle Scholar
• 9. Worldometer. www.worldometers.info/world-population/southern-asia-population/
  Google Scholar
• 10. Ferrell PB Jr, McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics 9(10), 1543–6 (2008).
  CASGoogle Scholar
• 11. Tantular IS, Kawamoto F. Distribution of G6PD deficiency genotypes among Southeast Asian populations.Trop. Med. Health 49(1), 97 (2021).
  MedlineGoogle Scholar
• 12. Hariprakash JM, Vellarikkal SK, Keechilat P et al. Pharmacogenetic landscape of DPYD variants in south Asian populations by integration of genome-scale data. Pharmacogenomics 19(3), 227–241 (2018).
  CASGoogle Scholar
• 13. Biswas M, Jinda P, Sukasem C. Pharmacogenomics in Asians: differences and similarities with other human populations. Expert Opin. Drug Metab. Toxicol. 19(1), 27–41 (2023).
  Medline CASGoogle Scholar
• 14. Ahsan T, Sajib AA. Drug-response related genetic architecture of Bangladeshi population. Meta Gene 21, 100585 (2019).
  Google Scholar
• 15. Dorji PW, Wangchuk S, Boonprasert K, Tarasuk M, Na-Bangchang K. Pharmacogenetic relevant polymorphisms of CYP2C9, CYP2C19, CYP2D6, and CYP3A5 in Bhutanese population. Drug Metab. Pers. Ther. 34(4), doi: 10.1515/dmpt-2019-0020 (2019).
  MedlineGoogle Scholar
• 16. Khan AR, Shah SH, Ajaz S, Firasat S, Abid A, Raza A. The prevalence of pharmacogenomics variants and their clinical relevance among the Pakistani population. Evol. Bioinform. Online 18, 11769343221095834 (2022).
  Google Scholar
• 17. Ranasinghe P, Sirisena N, Ariadurai JN et al. Pharmacogenomic variants affecting efficacy and toxicity of statins in a south Asian population from Sri Lanka. Pharmacogenomics 24(15), 809–819 (2023).
  CASGoogle Scholar
• 18. Sivadas A, Scaria V. Pharmacogenomic survey of Qatari populations using whole-genome and exome sequences. Pharmacogenomics J. 18(4), 590–600 (2018).
  Medline CASGoogle Scholar
• 19. Jithesh PV, Abuhaliqa M, Syed N et al. A population study of clinically actionable genetic variation affecting drug response from the Middle East. NPJ Genomic Med. 7(1), 1–11 (2022).
  MedlineGoogle Scholar
• 20. Bhasin MK. Genetics of Castes and Tribes of India: Somatometry. International Journal of Human Genetics 6(4), 323–356 (2006).
  Google Scholar
• 21. Shewade DG. Status of pharmacogenomics research in India during the last five years. Proc. Indian Natl Sci. Acad. 95, doi: 10.16943/PTINSA/2017/49229 (2017).
  Google Scholar
• 22. Sharma A, Kumari KM, Manohar HD, Bairy KL, Thomas J. Pattern of adverse drug reactions due to cancer chemotherapy in a tertiary care hospital in south India. Perspect. Clin. Res. 6(2), 109–115 (2015).
  MedlineGoogle Scholar
• 23. Saini VK, Sewal RK, Ahmad Y, Medhi B. Prospective observational study of adverse drug reactions of anticancer drugs used in cancer treatment in a tertiary care hospital. Indian J. Pharm. Sci. 77(6), 687–693 (2015).
  Medline CASGoogle Scholar
• 24. Sahana S, Bhoyar RC, Sivadas A et al. Pharmacogenomic landscape of Indian population using whole genomes. Clin. Transl. Sci. 15(4), 866–877 (2022).
  Medline CASGoogle Scholar
• 25. van Dyck CH, Swanson CJ, Aisen P et al. Lecanemab in early Alzheimer’s disease. N. Engl. J. Med. doi: 10.1056/NEJMoa2212948 (2022).
  MedlineGoogle Scholar
• 26. Jolly B, Scaria V. Letter to the editor: Alzheimer’s disease-associated APOE ε4 frequencies in Indian population genomes may suggest implications in lecanemab treatment. J. Prev. Alzheimers Dis. doi: 10.14283/jpad.2023.122 (2023).
  Google Scholar
• 27. Ramaiah M, Ramakrishna P. Pseudocholinesterase deficiency in an Indian community. J. Pharm. Pract. Community Med. 3(1), 27–30 (2017).
  Google Scholar
• 28. Al-Mahayri ZN, Patrinos GP, Wattanapokayakit S et al. Variation in 100 relevant pharmacogenes among Emiratis with insights from understudied populations. Sci. Rep. 10(1), 1–15 (2020).
  MedlineGoogle Scholar
• 29. Jain A, Bhoyar RC, Pandhare K et al. IndiGenomes: a comprehensive resource of genetic variants from over 1000 Indian genomes. Nucleic Acids Res. 49(D1), D1225–D1232 (2021).
  Medline CASGoogle Scholar
• 30. Wong L-P, Ong RT-H, Poh W-T et al. Deep whole-genome sequencing of 100 southeast Asian Malays. Am. J. Hum. Genet. 92(1), 52–66 (2013).
  Medline CASGoogle Scholar
• 31. Le VS, Tran KT, Bui HTP et al. A Vietnamese human genetic variation database. Hum. Mutat. 40(10), 1664–1675 (2019).
  Medline CASGoogle Scholar
• 32. Genomics Thailand. https://genomicsthailand.com/
  Google Scholar
• 33. Keeling NJ, Rosenthal MM, West-Strum D, Patel AS, Haidar CE, Hoffman JM. Preemptive pharmacogenetic testing: exploring the knowledge and perspectives of US payers. Genet. Med. 21(5), 1224–1232 (2019).
  MedlineGoogle Scholar
• 34. Nogueiras-Álvarez R. Pharmacogenomics in clinical trials: an overview. Front. Pharmacol. 14, 1247088 (2023).
  Medline CASGoogle Scholar
• 35. Simeonidis S, Koutsilieri S, Vozikis A, Cooper DN, Mitropoulou C, Patrinos GP. Application of economic evaluation to assess feasibility for reimbursement of genomic testing as part of personalized medicine interventions. Front. Pharmacol. 10, 830 (2019).
  MedlineGoogle Scholar